Background: Ischemic stroke is a major cause of mortality and long-term neurological disability worldwide. Although conventional vascular risk factors explain a substantial proportion of ischemic stroke burden, genetic susceptibility may contribute to inter-individual and population-level differences in risk. The angiotensin-converting enzyme insertion/deletion (ACE I/D) polymorphism is a biologically plausible vascular candidate variant because of its relationship with ACE activity, renin-angiotensin system regulation, endothelial function, vascular remodeling, and blood-pressure control. However, findings from Middle Eastern populations remain inconsistent. Objective: To systematically evaluate and quantitatively synthesize the association between ACE I/D polymorphism and ischemic stroke susceptibility in populations from the Middle East, with inferences restricted to the countries represented in the eligible evidence—Turkey, Egypt, Iran, and Iraq. Methods: This PRISMA 2020–based systematic review and meta-analysis was prospectively registered in PROSPERO (CRD420261406483). PubMed/MEDLINE, Scopus, and Web of Science were searched from inception to May 23, 2026 for observational genetic association studies reporting ACE I/D genotype or allele data in ischemic stroke cases and stroke-free Middle Eastern controls. Two reviewers independently conducted study selection, data extraction, and Newcastle-Ottawa Scale quality assessment. Random-effects ORs with 95% CIs were pooled under allele, dominant, recessive, homozygous, and heterozygous models, with sensitivity analyses excluding studies with HWE deviation, reconstructed counts, historical controls, and other strict-quality concerns. Results: Ten studies including 1,317 ischemic stroke cases and 979 controls were included, representing Turkey, Egypt, Iran, and Iraq. Across all primary random-effects models, ACE I/D polymorphism was not significantly associated with ischemic stroke susceptibility. The pooled estimates were: allele contrast D vs. I, OR = 1.16 (95% CI: 0.97–1.38); dominant model DD + ID vs. II, OR = 1.20 (95% CI: 0.91–1.57); recessive model DD vs. ID + II, OR = 1.20 (95% CI: 0.89–1.61); homozygous model DD vs. II, OR = 1.26 (95% CI: 0.94–1.70); and heterozygous model ID vs. II, OR = 1.14 (95% CI: 0.84–1.55). Heterogeneity ranged from low to moderate across most models, with the highest heterogeneity observed in the recessive model. Sensitivity analyses, particularly the exclusion of two studies with control-group Hardy–Weinberg equilibrium deviation, consistently attenuated the pooled estimates toward the null and did not support a robust association. Conclusion: Available evidence does not demonstrate a statistically robust association between ACE I/D polymorphism and ischemic stroke susceptibility in the populations studied in Turkey, Egypt, Iran, and Iraq. Although D-allele and DD-genotype carriers showed a weak non-significant trend toward increased risk, this pattern was not stable under sensitivity analyses. Given the null pooled findings, modest evidence base, predominance of unadjusted genotype-derived estimates, and absence of reliable stroke subtype-specific data, the current evidence does not support ACE I/D genotyping for clinical ischemic stroke risk prediction. These findings should not be generalized to Middle Eastern countries for which eligible evidence was unavailable.